Adrian Langleben

1.9k citations
55 papers · 1.1k · 1 hit paper · h-index 17

Impact in

  • Oncology top 5%
    • Lung Cancer Research Studies
    • Cancer Immunotherapy and Biomarkers
    • Cancer Treatment and Pharmacology
    • Lung Cancer Treatments and Mutations
    • Lung Cancer Diagnosis and Treatment

Papers in

    • Colorectal Cancer Treatments and Studies 11
    • Cancer Treatment and Pharmacology 10
    • Cancer Immunotherapy and Biomarkers 6
    • Lung Cancer Research Studies 5
    • Lung Cancer Treatments and Mutations 11

Adrian Langleben

52 papers receiving 1.1k citations

Adrian Langleben's Hit Papers

Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study 2021 · 165 citations
1650+1+3Years since publication50100150

Peers

Adrian Langleben
Comparison fields: 5 of 86
  • Oncology 725
  • Pulmonary and Respiratory Medicine 416
  • Genetics 114
  • Cancer Research 158
  • Toxicology 26
Replace Gabriella Parma with:
Gabriella Parma Italy
J. Bonneterre France
Fabrice Branle Switzerland
Javier Molina‐Cerrillo Spain
Hwee‐Yong Yap United States
Chung-Tsen Hsueh United States
Sophia Abraham United States
Ana Custodio Spain
Teresa Alonso‐Gordoa Spain
Katharine Hazell Switzerland
Adrian Langleben relative to Gabriella Parma Italy Gabriella Parma's profile →
Citations per field
00.5×2.6×
Gabriella Parma · 1×
Citations per year

Countries citing papers authored by Adrian Langleben

Since Specialization
Citations

This map shows the geographic impact of Adrian Langleben's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adrian Langleben with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adrian Langleben more than expected).

Fields of papers citing papers by Adrian Langleben

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adrian Langleben. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adrian Langleben. The network helps show where Adrian Langleben may publish in the future.

Co-authors

The 25 scholars most cited alongside Adrian Langleben, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Adrian Langleben Line = papers co-authored together Adrian Langleben links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 55 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study
Hit paper breakdown →
2021165
2 1996100
3 199989
4 199987
5 199584
6 200856
7 199352
8 200052
9 199747
10 199845
11
Relationship between O6-methylguanine-DNA methyltransferase levels and clinical response induced by chloroethylnitrosourea therapy in glioma patients.
199933
12 200826
13 201323
14 198321
15 200917
16
Recombinant GM-CSF in patients with poor graft function after bone marrow transplantation.
199017
17 200116
18 200815
19
An oncology perspective on the benefits and cost of combined androgen blockade in advanced prostate cancer.
200315
20 200014

About Adrian Langleben

Adrian Langleben is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Genetics and Toxicology, having authored 55 papers that have together received 1.1k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (11 papers), Lung Cancer Treatments and Mutations (11 papers), Cancer Treatment and Pharmacology (10 papers), Bioactive Compounds and Antitumor Agents (7 papers), Cancer Immunotherapy and Biomarkers (6 papers), Glioma Diagnosis and Treatment (5 papers), Lung Cancer Research Studies (5 papers) and Hepatocellular Carcinoma Treatment and Prognosis (4 papers). The work is most often cited by research in Oncology (725 citations), Pulmonary and Respiratory Medicine (416 citations), Genetics (114 citations), Cancer Research (158 citations) and Toxicology (26 citations). Adrian Langleben has collaborated with scholars based in Canada, United States and Taiwan. Frequent co-authors include George Shenouda, Jean‐Guy Villemure, Henrik Rasmussen, Ephraim S. Casper, Alexander S. Rosemurgy, Jules E. Harris, Eleanor Elstein, Themistocles L. Assimes, Samy Suissa and Gordon H. Baltuch. Their work appears in journals such as Journal of Clinical Oncology, Cancer, Journal of Thoracic Oncology, Lung Cancer and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact